Compare GSK plc (GSK) vs iShares Russell 2000 ETF (IWM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs iShares Russell 2000 ETF — how do they compare? GSK plc trades at $46.5 (market cap $91.88B), while iShares Russell 2000 ETF trades at $278.93 (market cap $77.70B). The key difference: GSK plc is the larger of the two by market cap, and GSK plc pays a 3.9% dividend while iShares Russell 2000 ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and iShares Russell 2000 ETF for 83 Days on average.
| GSK | IWM | |
|---|---|---|
Market Cap | $91.88B | $77.70B |
Volume | 7,730,529 | 35,598,983 |
Sector | Health | — |
52-Week High | $61.18 | $305.06 |
52-Week Low | $43.24 | $229.13 |
Typical Hold Time | 93 Days | 83 Days |
Enterprise Value | $111.88B | — |
Dividend Yield | 3.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.50, down 1.11% with bearish technical signals, though RSI levels suggest potential oversold conditions. Fundamentally, the company shows strong profitability with 72.73% gross margins and consistent earnings beats, while maintaining a reasonable P/E of 14.89. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite facing an HIV patent cliff.
GSK presents a mixed investment case with strong fundamentals and pipeline growth offset by technical weakness and patent expiration risks. The company's £40B sales target and cost-saving initiatives provide upside potential, while analyst consensus leans cautious with 55% hold ratings. Key risks include execution of pipeline development and competitive pressures in core markets.
IWM trades at $278.93, up 0.44% with a bearish technical signal from moving averages. The ETF faces headwinds as small-caps underperform the broader market, with recent news highlighting decade-long trailing of the S&P 500. Technical indicators show mixed signals with RSI neutral but ADX signaling strong bearish momentum. Support levels cluster around $272-$276 while resistance sits at $279-$282.
The outlook remains cautious given small-cap sensitivity to interest rates and economic conditions. Recent Fed rate hikes pressure the sector, though some rotation potential exists if market breadth improves. Key risks include continued underperformance versus large-caps and sensitivity to tightening financial conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About iShares Russell 2000 ETF
The ETF is designed to track the performance of the securities and the stocks in the Russell 2000 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on IWM →
